Nona Biosciences Announces Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapy Development
Umoja Biopharma
Cancer Treatment Drug Developer
Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
On September 13, Harbour BioMed (Suzhou) Co., Ltd. announced a multi-target antibody development collaboration with Umoja Biopharma. Umoja Biopharma is a transformative immunotherapy company dedicated to developing more accessible and effective off-the-shelf CAR-T cell therapies in the fields of oncology and autoimmune diseases. This collaboration will leverage Harbour BioMed's proprietary fully human heavy chain antibody (HCAb) platform technology to produce novel in vivo CAR-T cell therapies.
Fully Human HCAb, Due to Its Compact Size, Simple Structure, and Precise Binding Ability, Can Significantly Reduce the Immunogenicity of Antibodies and Bring Greater Flexibility and Diversity to CAR Functional Design. This Collaboration Will Utilize Harbour BioMed (Suzhou) Co., Ltd.'s HCAb Harbour Mice® Platform and HCAb Library Screening Platform Based on CAR Function (NonaCarFxTM), as Well as Umoja Biopharma, Inc.'s VivoVecTM Platform, to Develop Novel In Vivo CAR-T Cell Therapies and Further Expand the Potential Applications of This Innovative Delivery Technology.
Dr. Wang Jinsong, Chairman of Harbour BioMed (Suzhou) Co., Ltd., said: "We are delighted to collaborate with Umoja Biopharma, a leader in the field of cell and gene therapy. We believe that, based on HCAb Harbour Mice®Together with the NonaCarFxTM platform and our extensive experience in oncology and immunology, Harbour BioMed will support Umoja Biopharma in developing innovative CAR-T therapies, ultimately benefiting patients worldwide.”
Byoung Ryu, Ph.D., Executive Vice President of Research and Vector Biology at Umoja Biopharma, stated: "As we continue to advance the field of CAR-T cell therapy towards the development of in vivo direct-administration CAR therapies, Harbour BioMed (Suzhou) Co., Ltd. has been an outstanding partner. Harbour BioMed has demonstrated remarkable strength in developing CAR candidate drugs, and we look forward to collaborating to develop multiple in vivo candidates, ultimately helping to improve patient treatment outcomes.”
Source: Harbour BioMed